1. Alsaadoni H, Çaykara B, Pençe S, Pençe HH, Bademler S (2019) The expression levels of miR-655-3p, miR127-5p, miR-369-3p, miR-544a in gastric cancer. Turkish Journal of Biochemistry 44:487–491
2. Andersson Å, Covacu R, Sunnemark D, Danilov AI, Dal Bianco A, Khademi M, Wallström E, Lobell A, Brundin L, Lassmann H (2008) Pivotal advance: HMGB1 expression in active lesions of human and experimental multiple sclerosis. Journal of Leukocyte Biology 84:1248–1255
3. Ayzenberg I, Hoepner R, Kleiter I (2016) Fingolimod for multiple sclerosis and emerging indications: appropriate patient selection, safety precautions, and special considerations. Therapeutics and Clinical Risk Management 12:261
4. Brinkmann V, Davis MD, Heise CE, Albert R, Cottens S, Hof R, Bruns C, Prieschl E, Baumruker T, Hiestand P (2002) The immune modulator FTY720 targets sphingosine 1-phosphate receptors. Journal of Biological Chemistry 277:21453–21457
5. Chiba K, Yanagawa Y, Masubuchi Y, Kataoka H, Kawaguchi T, Ohtsuki M, Hoshino Y (1998) FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. The Journal of Immunology 160:5037–5044